Markets

Rare disease biotech Homology Medicines sets terms for $100 million IPO

Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, announced terms for its IPO on Monday.

The Bedford, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Homology Medicines would command a fully diluted market value of $529 million.

Homology Medicines was founded in 2015 and plans to list on the Nasdaq under the symbol FIXX. BofA Merrill Lynch, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of March 26, 2018.

The article Rare disease biotech Homology Medicines sets terms for $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More